Alliance Pharma acquires Perrigo scar treatments

28 March 2022 - Deborah Wilkes

Premium

Alliance Pharma has accessed the OTC scar treatment market in the US by acquiring the ScarAway brand and US rights to Kelo-cote from Perrigo for USD19.4 million in cash.

Click tags below for more information on topics:

Alliance Pharma Perrigo

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: